Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms
Key facts
- Who runs it
- PENTA Foundation
- Where
- Germany, Greece, Spain, Switzerland, and United Kingdom6 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 522 people enrolled
- Started
- 7 Jul 2021
- Ended
- 25 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)
- Record updated
- 18 April 2025
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Children of any age presenting to the Emergency Room with an acute illness (present for 14 days or less) with Temperature ≥38.0°C measured at presentation or reported within the previous 24 hours; AND at least two of the below:; Cough; Abnormal sounds on chest auscultation (crackles, reduced breath sounds, bronchial breathing, wheezing); Clinical signs of dyspnea (chest indrawing, nasal flaring, grunting); Signs of respiratory dysfunction: tachypnoea for age or decreased oxygen saturation (<92% in room air); Signs of reduced general state: poor feeding, vomiting or lethargy/drowsiness
- At time of screening:; Patient has undergone first assessment by managing clinical team (doctor or nurse, incl. triage); Hospitalisation is not yet determined, i.e. neither by clinical presentation definitely requiring hospitalisation (e.g. per local guideline) nor by fixed decision of managing clinical team; admission to a short-stay unit or surveillance unit is not considered a hospitalisation for this trial; Antibiotic treatment or hospitalisation is being considered; The rapid syndromic diagnostic test result can be awaited for up to 4 hours before the decision to discharge the patient or to initiate antibiotic treatment is made
Who cannot take part
- Patients with a severe underlying medical condition dictating management decisions including hospitalisation and/or antibiotic treatment (e.g cystic fibrosis, immunosuppression)
- Less than 14 days since the last episode of respiratory tract infection
- Any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases or patients with short life expectancy
- Development of ARTI more than 48 hours after hospital admission (hospital acquired)
- Confirmed pregnancy and/or breastfeeding
- Inability to obtain informed consent
- Alternative noninfectious diagnosis that explains clinical symptoms
Where is this trial?
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a randomized controlled trial where participants are randomly assigned in a 1:1 ratio to either a rapid test group or a control group. Standard care is provided in the control group. Follow-up is conducted until discharge from the hospital, followed by telephone check-ins and completion of questionnaires by the participants themselves or their proxies until 30 days after randomization. Children of any age presenting at selected participating sites with acute respiratory tract infections, where initial treatment decisions are uncertain, are eligible to participate. The study aims to enrol 520 participants and involves Paediatric Emergency Rooms across Europe.
The 2 groups in the trial
- Intervention (Device)Treatment being tested
Diagnostic Test: BioFire A molecular rapid syndromic testing platform, using the following panel: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) In addition to standard of care
Treatment: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)
- Control (Standard of Care)No study treatment, for comparison
Standard of Care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms - Paediatric
- Record updated
- 18 April 2025